Stockscreener 앱 받기
10.65
0.09%
-0.010
전일 마감가:
$10.66
열려 있는:
$10.57
하루 거래량:
2.70M
Relative Volume:
0.68
시가총액:
$2.77B
수익:
$6.29B
순이익/손실:
$750.00M
주가수익비율:
3.6979
EPS:
2.88
순현금흐름:
$586.00M
1주 성능:
+2.60%
1개월 성능:
+17.68%
6개월 성능:
-29.00%
1년 성능:
-47.51%
1일 변동 폭
$10.50
$10.71
1주일 범위
$9.9831
$10.71
52주 변동 폭
$8.01
$21.05
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
OGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
10.65 | 2.67B | 6.29B | 750.00M | 586.00M | 2.88 |
|
LLY
Lilly Eli Co
|
755.39 | 676.48B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.06 | 423.36B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
218.34 | 373.87B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
124.12 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
82.81 | 209.89B | 63.43B | 16.42B | 14.72B | 6.49 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
WBI Investments LLC Invests $946,000 in Organon & Co. $OGN - MarketBeat
Organon & Co. $OGN Shares Sold by AQR Capital Management LLC - MarketBeat
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amundi Acquires 102,715 Shares of Organon & Co. $OGN - MarketBeat
Why Organon (OGN) Stock Is Trading Up Today - Yahoo Finance
New Vernon Capital Holdings II LLC Buys 230,650 Shares of Organon & Co. $OGN - MarketBeat
Organon & Co. $OGN Position Boosted by Gotham Asset Management LLC - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $15.05 Million Holdings in Organon & Co. $OGN - MarketBeat
Raymond James Financial Inc. Has $4.74 Million Stake in Organon & Co. $OGN - MarketBeat
Organon (OGN) Stock Declines While Market Improves: Some Information for Investors - sharewise.com
Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN) - 富途牛牛
Direct Relief Announces 2025 Organon Community Health Awards Recipients - ReportAlert
Kuehn Law Encourages Investors of Organon & Co. to Contact Law Firm - MarketScreener
Organon & Co. $OGN Stake Boosted by Banque Transatlantique SA - MarketBeat
ADAR1 Capital Management LLC Has $149,000 Stock Holdings in Organon & Co. $OGN - MarketBeat
Organon (NYSE:OGN) Valuation After FDA Approvals Expand Its Osteoporosis and Bone Health Portfolio - Yahoo Finance
Organon and Henlius get FDA nod for Amgen biosimilars - MSN
Organon & Co. $OGN Position Lessened by Caption Management LLC - MarketBeat
Co. stock movementJuly 2025 Rallies & Stepwise Entry/Exit Trade Alerts - Newser
Organon & Co. shares rise 3.45% intraday after HKEX censures Henlius Biotech, rebukes former CEO. - AInvest
Organon And Henlius Are Latest To Receive Denosumab Nod In US - insights.citeline.com
Organon and Henlius get FDA nod for Amgen biosimilars (OGN) - Seeking Alpha
US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Yahoo Finance
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Placera.se
Major Breakthrough: FDA Approves Two New Biosimilars to Treat Millions with Bone Health Conditions - Stock Titan
Organon's Upside Potential: Can Biosimilars and Women’s Health Drive a Re-rating? - AInvest
Will Raised Revenue Guidance and New Launches Shift Organon's (OGN) Growth Outlook? - simplywall.st
How Investors Are Reacting To Organon (OGN) Lifting 2025 Guidance and CEO Share Purchase - Yahoo Finance
Organon & Co. (OGN) Advances VTAMA Cream, Strengthens Women’s Health Portfolio - MSN
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Organon & Co. shares rise 1.57% intraday after Trane Technologies launches Season 5 of Healthy Spaces podcast. - AInvest
Organon & Co. shares fall 1.02% intraday after Genentech files BPCIA complaint against Organon and Henlius. - AInvest
Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar - insights.citeline.com
Does Organon's Raised 2025 Guidance Signal a Turning Point for OGN Investors? - simplywall.st
Kahn Brothers' Q2 2025 13F Filing: Alphabet, Comcast, and Organon Highlights - AInvest
Organon in charts: Women's Health revenue up ~3% Y/Y in Q2 - MSN
Roche Sues Organon in First Case Over Biosimilar Copy of Perjeta - Bloomberg Law News
There May Be Some Bright Spots In Organon's (NYSE:OGN) Earnings - Yahoo Finance
Organon & Co. (OGN) Stock Price, News & Analysis - MarketBeat
Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool
OGN’s Market Whiplash: -52.64% YTD Decline, -4.30% Plunge in 30 Days - investchronicle.com
Bullish Organon Insiders Loaded Up On US$651.6k Of Stock - 富途牛牛
Organon & Co.'s Q2 2025 Earnings Call: Unraveling Key Contradictions in Capital Allocation, Nexplanon Growth, and Financial Forecasts - AInvest
LPL Financial LLC Has $4.87 Million Holdings in Organon & Co. (NYSE:OGN) - Defense World
NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation - The Malaysian Reserve
Ex-Dividend Reminder: Cencora, Organon and Esquire Financial Holdings - Nasdaq
5 Must-Read Analyst Questions From Organon’s Q2 Earnings Call - Yahoo Finance
OGN Q2 Deep Dive: Flat Sales, Margin Pressure, and Strategic Shifts Highlight Quarter - Yahoo Finance
Organon's Valuation: Discounted Due to Structural Challenges - AInvest
Organon: Valuation Discount Offset By Structural Headwinds (NYSE:OGN) - Seeking Alpha
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
1.05%
자본화:
|
볼륨(24시간):